- No file added yet -

Interview with Dr. Mellinghoff from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

media

posted on 2023-04-03, 20:25 authored by Igor Vivanco, H. Ian Robins, Daniel Rohle, Carl Campos, Christian Grommes, Phioanh Leia Nghiemphu, Sara Kubek, Barbara Oldrini, Milan G. Chheda, Nicolas Yannuzzi, Hui Tao, Shaojun Zhu, Akio Iwanami, Daisuke Kuga, Julie Dang, Alicia Pedraza, Cameron W. Brennan, Adriana Heguy, Linda M. Liau, Frank Lieberman, W. K. Alfred Yung, Mark R. Gilbert, David A. Reardon, Jan Drappatz, Patrick Y. Wen, Kathleen R. Lamborn, Susan M. Chang, Michael D. Prados, Howard A. Fine, Steve Horvath, Nian Wu, Andrew B. Lassman, Lisa M. DeAngelis, William H. Yong, John G. Kuhn, Paul S. Mischel, Minesh P. Mehta, Timothy F. Cloughesy, Ingo K. Mellinghoff

mp3 file (11 MB). In the May edition of the Cancer Discovery podcast, Science Writer Elizabeth McKenna talks with Ingo K. Mellinghoff about his paper, which suggests that the disappointing clinical activity of first-generation EGFR inhibitors in glioblastoma versus lung cancer may be attributed to the different conformational requirements of mutant EGFR in these two cancer types.

History

ARTICLE ABSTRACT

Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to the EGFR inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EGFR EC mutations display EGFR addiction. In contrast to KD mutants found in lung cancer, glioma-specific EGFR EC mutants are poorly inhibited by EGFR inhibitors that target the active kinase conformation (e.g., erlotinib). Inhibitors that bind to the inactive EGFR conformation, however, potently inhibit EGFR EC mutants and induce cell death in EGFR-mutant GBM cells. Our results provide first evidence for single kinase addiction in GBM and suggest that the disappointing clinical activity of first-generation EGFR inhibitors in GBM versus lung cancer may be attributed to the different conformational requirements of mutant EGFR in these 2 cancer types.Significance: Approximately 40% of human glioblastomas harbor oncogenic EGFR alterations, but attempts to therapeutically target EGFR with first-generation EGFR kinase inhibitors have failed. Here, we demonstrate selective sensitivity of glioma-specific EGFR mutants to ATP-site competitive EGFR kinase inhibitors that target the inactive conformation of the catalytic domain. Cancer Discov; 2(5); 458–71. ©2012 AACR.Read the Commentary on this article by Park and Lemmon, p. 398.This article is highlighted in the In This Issue feature, p. 377.